Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Shanghai, Shanghai Municipality

OncologyPhase IIIListed · 688266.SH

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.

5w agoTrial registeredJun 8, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE3 registered
Jul 1, 2026
Neuroendocrine Carcinoma · NOT_YET_RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
ClinicalTrials.gov · NCT07595913 (opens the source filing in a new tab)
Trial
PHASE1 registered
May 12, 2026
Healthy · ACTIVE_NOT_RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.
ClinicalTrials.gov · NCT07565597 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 21, 2026
Small Cell Lung Cancer · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
ClinicalTrials.gov · NCT07231445 (opens the source filing in a new tab)
Trial
PHASE2 registered
Dec 2, 2025
Biliary Tract Carcinoma · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
ClinicalTrials.gov · NCT07099547 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Sep 23, 2025
Cervical Cancer · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
ClinicalTrials.gov · NCT07080216 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Sep 23, 2025
Small Cell Lung Cancer, Neuroendocrine Carcinoma · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
ClinicalTrials.gov · NCT07038096 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
May 20, 2025
Advanced Solid Tumor · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
ClinicalTrials.gov · NCT06938880 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
May 16, 2025
Lymphoma · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
ClinicalTrials.gov · NCT06883526 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Sep 2, 2024
Small Cell Lung Cancer, Neuroendocrine Cancer · RECRUITING · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
ClinicalTrials.gov · NCT06283719 (opens the source filing in a new tab)
Trial
PHASE3 registered
Sep 4, 2021
Alopecia Areata · COMPLETED · sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
ClinicalTrials.gov · NCT05051761 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 81%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 1.00name similarity 100% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the trial record at 0.97name similarity 100% · semantic similarity 80% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.96name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.
5w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
6mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
8mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
8mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Mar 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Mar 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE3 registered

PHASE1 registered

PHASE1 registered

PHASE2 registered

PHASE1/PHASE2 registered

PHASE1/PHASE2 registered

PHASE1/PHASE2 registered

PHASE1/PHASE2 registered

PHASE1/PHASE2 registered

PHASE3 registered